USP Announces Corrections to General Chapter <1132.1> on Residual Host Cell Protein Measurement
Recommendation

Tuesday, 10 November 2026 9 .00 - 17.00 h
The United States Pharmacopeia (USP) has announced minor corrections to General Chapter <1132.1> Residual Host Cell Protein Measurement in Biopharmaceuticals by Mass Spectrometry. The chapter was originally published in Pharmacopeial Forum 49(3) and subsequently approved for publication on 01 November 2024, in USP-NF 2025, Issue 1.
The following errata were published on 31 January 2025, and all changes will take effect on 01 May 2025:
- Section 1. INTRODUCTION AND SCOPE – In paragraph 3: Change Residual HCP ELISA to: HCP ELISA.
- Section 4. SAMPLE PREPARATION, CHROMATOGRAPHIC SEPARATION, AND MASS SPECTROMETRY ANALYSIS – In paragraph 4 in 4.1 Sample Preparation: Change product (or polysorbate) to: product protein (or polysorbate).
- Section 5. QUANTITATION OF HCPS – In three instances in 5.1 Methods for HCP Quantitation: Change product to: product protein.
- Section 7. BEST PRACTICES FOR REPORTING DATA FROM ELISA VERSUS LC-MS/MS – In paragraph 1 in 7.3 Comparison of ELISA and LC-MS/MS HCP Results: Change the comparing to: comparing.
For a comprehensive list of errata, refer to the USP-NF Errata Table.
Additionally, please see the Notice of Intent to Revise, published on 01 November 2024, for further details.
Related GMP News
05.11.2026Eurachem Publishes Webinar Recording on the Fitness for Purpose of Analytical Methods Guide
05.11.2026Recent Publications Highlighting Topics to be Discussed at PharmaLab 2026
05.11.2026Meet the AQCG Board Members at PharmaLab 2026
05.11.2026FDA Warning Letter: When Test Procedures Allow Retesting Until an Acceptable Result is Obtained
21.10.2026EMA Updates Information Page on Bioequivalence Guidelines
21.10.2026BP Publishes new Draft Texts


